Interleukin-6 identified as an important factor in hypoxia- and aldehyde dehydrogenase-based gefitinib adaptive resistance in non-small cell lung cancer cells

Gefitinib resistance and relapse of the disease were the greatest challenges facing clinical therapy of non-small-cell lung cancer (NSCLC). Of note, regarding the hypoxia condition in solid tumor tissues in vivo, roles of hypoxia in gefitinib adaptive resistance and its association with lung cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Shi-Min, Lei, Hui-Min, Ding, Xu-Ping, Sun, Fan, Zhang, Chun, Tang, Ya-Bin, Chen, Hong-Zhuan, Shen, Ying, Zhu, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588073/
https://www.ncbi.nlm.nih.gov/pubmed/28927099
http://dx.doi.org/10.3892/ol.2017.6613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588073/
https://www.ncbi.nlm.nih.gov/pubmed/28927099
http://dx.doi.org/10.3892/ol.2017.6613

Ejemplares similares